metformin has been researched along with itraconazole in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Choi, YH; Lee, BK; Lee, MG; Lee, U | 1 |
| Bhattarai, D; Choi, Y; Hyeon Han, S; Jang, Y; Lee, K; Singh, S | 1 |
| Aoki, D; Banno, K; Kobayashi, Y; Kunitomi, H; Tominaga, E | 1 |
| Bartosch, C; Henriques Abreu, M; Nunes, M; Ricardo, S | 1 |
| Dubashi, B; Ganesan, P; Goenka, L; Selvarajan, S | 1 |
| Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W | 1 |
5 review(s) available for metformin and itraconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.
Topics: Antineoplastic Agents; Aspirin; Digoxin; Diphosphonates; Drug Approval; Drug Discovery; Drug Repositioning; Humans; Itraconazole; Metformin; Nelfinavir; Thalidomide | 2016 |
Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antiparasitic Agents; Carcinoma, Ovarian Epithelial; Diphosphonates; Drug Repositioning; Female; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Ivermectin; Metformin; Ovarian Neoplasms | 2019 |
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.
Topics: Diphosphonates; Drug Repositioning; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Ivermectin; Metformin; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ritonavir | 2020 |
Use of "Repurposed" Drugs in the Treatment of Epithelial Ovarian Cancer: A Systematic Review.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Metformin; Ovarian Neoplasms; Proton Pump Inhibitors | 2022 |
1 trial(s) available for metformin and itraconazole
| Article | Year |
|---|---|
Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer.
Topics: Area Under Curve; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Lung Neoplasms; Metformin; Midazolam; Prospective Studies; Pyrimidines; Pyrroles; Rifampin; Topotecan | 2022 |
10 other study(ies) available for metformin and itraconazole
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2.
Topics: Animals; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hypoglycemic Agents; Intestinal Mucosa; Intestines; Itraconazole; Liver; Male; Membrane Proteins; Metformin; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2010 |